Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Enzo Clinical Lab and DiaSorin Collaborate

Published: Friday, October 18, 2013
Last Updated: Friday, October 18, 2013
Bookmark and Share
The collaboration will enable the DiaSorin to provide physician-clients in metropolitan New York with advanced diagnostic tools.

“Our agreement with DiaSorin has multiple benefits that, in addition to providing additional cutting edge diagnostic technology to physicians and their patients from a global leader in the in vitro diagnostics field, also reflects an acknowledgement of the excellent and expanding capabilities of our Lab, a center of excellence, in evolving medical science,” said Barry Weiner, Enzo President.

As part of the agreement, Enzo Clinical Labs has added two new DiaSorin LIAISON® XL Analyzers, a new high throughput, chemiluminescent, random access analyzer that provides a menu of over 30 assays. The system requires no daily maintenance with most tests and can manage up to 25 different assays on board.

“We are excited to collaborate with Enzo to provide high quality automated testing solutions to best serve their clients with an opportunity for growth and improved patient care,” said John Eskdale, DiaSorin President. “The LIAISON® XL, with its expanded menu, will offer Enzo a competitive advantage in the areas of specialty testing which include infectious disease, growth, hypertension, and bone & mineral.”

Enzo Labs initially will offer a number of DiaSorin LIAISON® XL tests to its customers, including the LIAISON® 25 OH Vitamin D TOTAL assay, which measures both 25-OH D2 and 25-OH D3 metabolites to accurately assess Vitamin D sufficiency. Enzo will also offer DiaSorin’s CMV IgM and Borrelia burgdorferi assays, and is currently evaluating the company’s new LIAISON® Direct Renin and Aldosterone assays. These tests are the only fully automated, FDA cleared chemiluminescent assays available for the diagnosis and treatment of certain types of hypertension and primary aldosteronism.

Enzo and DiaSorin will continue to evaluate the entire line of LIAISON® assays to assure Enzo’s clientele of the availability of the most advanced and high quality immunoassays.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Enzo and NIH File Patent Application for Autoimmune Diseases
Collaborators filed a patent application for the management of autoimmune diseases that may include age-related macular degeneration (AMD), which is a leading cause of blindness in the United States.
Thursday, May 09, 2013
Enzo Biochem Announces Expanded Distribution Agreement with Japan’s Cosmo Bio
Under the terms of the arrangement, Cosmo Bio will assume a leadership position in Japan in the promotion, sales, and high level technical and customer support for Enzo Life Sciences products.
Wednesday, March 21, 2012
Scientific News
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Biomarker Finder Adjusts On the Fly
Rice University scientists build better tool to find signs of disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos